SoniVie

Company Overview

Snapshot

Founded in August 2014, SoniVie operates with 1–10 employees and has raised a total of $73.26 million across 3 funding rounds from 6 investors. The company was acquired by Boston Scientific in March 2025.

Business overview

SoniVie is a medical device company focused on developing a system for the treatment of pulmonary hypertension (PAH). Its core technology is the therapeutic intravascular ultrasound (TIVUS) catheter, designed to selectively damage nerves associated with disease activity within the pulmonary artery without harming vessel walls or adjacent tissues. This treatment aims to significantly slow disease progression. The TIVUS system is approved for sale in markets regulated by the CE mark and has received Breakthrough Device Designation from the FDA for both pulmonary arterial hypertension and renal artery denervation. SoniVie serves the healthcare industry, specifically targeting hospitals, doctors, and clinics with its vascular treatment solutions.

Strategic signal

In March 2025, SoniVie was acquired by Boston Scientific for up to $540 million. This acquisition validates SoniVie's innovative approach to hypertension treatment and signals a significant strategic move by Boston Scientific to expand its portfolio in the cardiovascular medical device market, indicating strong investor confidence in SoniVie's TIVUS system and its potential impact on patient care.

Company Intelligence Q&A

What was the most significant recent corporate event for SoniVie?

SoniVie was acquired by Boston Scientific in March 2025 for up to $540 million, marking a major exit for the company and a strategic expansion for Boston Scientific in the hypertension treatment market.

When did SoniVie receive FDA Breakthrough Device Designation for its TIVUS system for pulmonary arterial hypertension?

SoniVie received FDA Breakthrough Device Designation for its TIVUS system in the treatment of pulmonary arterial hypertension (PAH) in September 2019.

What was a key regulatory milestone for SoniVie's TIVUS system in December 2020?

In December 2020, SoniVie's TIVUS system received FDA Breakthrough Device Designation for use in renal artery denervation for the treatment of resistant hypertension.

Which investors participated in SoniVie's funding round in January 2023?

In January 2023, SoniVie raised funding from lead investor Andera Partners.

When did SoniVie appoint Raymond W. Cohen as Chairman of its Board of Directors?

SoniVie appointed veteran medtech executive Raymond W. Cohen as Chairman of its Board of Directors in November 2024.